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Abstract 
Olfactory  neuroblastoma  (esthesioneuro  -
blastoma) is a rare malignant tumor of neu-
roectodermal  origin.  With  only  about  1,000
cases reported, there are no clear guidelines
regarding  management  of  this  disease.
Intracranial extension and orbital involvement
have been shown to be independent risk fac-
tors  associated  with  poorer  outcomes.  We
hereby report a case of a 46-year old male pre-
sented with an 8-month history of progressive
nasal obstruction and intermittent right-sided
epistaxis  associated  with  anosmia  and
increased pressure sensation in and around
the  right  eye.  Further  evaluation  revealed  a
large  enhancing  heterogeneous  cystic  and
solid mass in the right nasal cavity measuring
5.0¥5.3¥4.6 cm with extension superiorly into
the  anterior  cranial  fossa  and  frontal  lobes,
ethmoid and sphenoid sinuses. A biopsy of this
mass confirmed high grade olfactory neurob-
lastoma.  Because  of  the  intra-cranial  exten-
sion, a decision was made to start neoadjuvant
chemotherapy  with  cisplatin  and  etoposide.
The  patient  had  very  good  response  to  this
treatment on a repeat imaging study and went
on to have resection of this mass. Post-opera-
tively,  he  received  radiation  therapy  to  the
tumor bed and 2 more cycles of chemotherapy.
He  has  been  followed  now  for  more  than  8
months  with  no  evidence  of  disease  recur-
rence.
Introduction
Olfactory  neuroblastoma  (esthesioneuro  -
blastoma) is a rare malignant tumor of neu-
roectodermal origin. It is thought to arise from
the olfactory epithelium that lines the superior
third of the nasal septum, cribriform plate, and
superior  turbinates.  Since  Berger  and  Luc’s
initial  report  in  1924,  approximately  1,000
cases have been reported with 5-year survival
rate in the order of 60-70%.
1 The most common
symptoms at the time of presentation are nasal
obstruction (52%), epistaxis (42%), exophthal-
mos (19%), and headache (19%).
2The age distri-
bution of patients is unimodal with the majority
of patients presenting at diagnosis in the 4th and
5th decades of life yet presentation in patients
under 30 years of age is not uncommon.
3
There is no universally accepted staging sys-
tem for olfactory neuroblastoma. Kadish et al
were  the  first  to  propose  a  staging  system
based on a series of 17 patients.
4 Patients were
classified into 3 stages: stage A, tumor con-
fined to nasal cavity; stage B, tumor extends to
one  or  more  of  the  paranasal  sinuses;  and
stage C, where the tumor extends beyond the
nasal cavity and paranasal sinuses. Morita et al
modified the Kadish staging system by re-clas-
sifying  patients  with  lymph  node  or  distant
metastases as stage D.
5
The two most important factors influencing
prognosis in patients with olfactory neuroblas-
toma are extent of disease at diagnosis and
histologic  grade.
6,7 Survival  rates  have  been
reported  to  correlate  with  S-100  protein
immunoreactivity  and  a  low  Ki-67  labeling
index  (<10%).
8 Intracranial  extension  and
orbital  involvement  have  been  shown  to  be
independent risk factors associated with poor-
er outcomes.
9 Lymph node status and age are
also considered useful predictors of outcome.
3
A study of 311 patients based on Surveil  -
lance, Epidemiology and End Results (SEER)
database showed that disease-specific survival
at  10  years  correlated  with  modified  Kadish
staging (83%, 49%, 39%, and 13% for stages A,
B, C, and D, respectively).
3There are no report-
ed  randomized  trials  to  guide  treatment  in
patients  with  olfactory  neuroblastoma.  The
combination  of  surgery  and  adjuvant  radio-
therapy is the most widely used approach in
patients  with  locally  advanced  disease.
9,10 A
review of 390 cases (1990-2000) showed that
surgery plus radiation resulted in a five-year
survival rate of 65%, compared with 48% with
surgery alone.
6
Chemotherapy  has  been  advocated,  either
in the adjuvant or neoadjuvant setting, in vary-
ing  protocols.
11-13 The  capacity  of  induction
chemotherapy  to  convert  a  previously  unre-
sectable presentation to one that is capable of
complete surgical extirpation has been report-
ed.
11 The  following  is  a  case  report  that  is
emblematic of successful multimodality man-
agement  in  a  patient  with  locally  advanced
olfactory  neuroblastoma  with  intracranial
spread.
Case Report
A  46-year  old  male  presented  with  an  8-
month history of progressive nasal obstruction
and intermittent right-sided epistaxis.  He had
experienced  several  weeks  of  anosmia  and
increased pressure sensation in and around
the right eye with decreased visual acuity and
diplopia on rightward gaze. His general health
was without significant comorbidities. He was
a nonsmoker and worked as an aircraft painter.  
On examination, nasal endoscopy revealed a
bulging mass arising from a region superior to
the middle turbinate on the right side. An MRI
of the sinuses showed a large enhancing het-
erogeneous cystic and solid mass in the right
nasal  cavity  measuring  5.0¥5.3¥4.6  cm  with
extension superiorly into the anterior cranial
fossa and frontal lobes, ethmoid and sphenoid
sinuses with compression and erosion of the
medial wall of the right maxillary sinus (Figure
1). A PET/CT scan showed intense radiotracer
uptake in the large soft tissue mass that in the
posterosuperior  nasal  cavity  with  Standard
Uptake Value (SUV) of 35 without evidence of
regional or distant spread. A biopsy of the mass
revealed a high-grade olfactory neuroblastoma
with extensive tumor necrosis, apoptosis with
Ki67 staining of greater than 60%.
Immunohistochemical  staining  confirmed
the tumor was positive for CAM5.2, neuron-
specific  enolase,  synaptophysin,  pankeratin
and S-100 and negative for chromogranin A,
TTF-1, CD99 and lymphoid and hematopoietic
factors.  The  tumor  was  considered  to  be  a
Hyam’s grade IV tumor, Kadish stage C. 
Neoadjuvant  therapy  was  considered
because  of  the  intracranial  spread  of  tumor
that would necessitate resection a consider-
able portion of the frontal lobe of the brain in a
attempting to obtain negative margins at the
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time  of  surgery.  Neoadjuvant  chemotherapy
was  initiated  with  two  cycles  (cisplatin  75
mg/m
2 on day 1 and etoposide 100 mg/m
2 on
days 1, 2, and 3, cycles repeated every 21 days).
During this phase treatment, the patient’s per-
sistent  headache,  periorbital  pressure  and
diplopia  all  resolved.  Post-induction  MRI
demonstrated a major interval decrease in the
size of the mass with resolution of the previ-
ous noted imaging-based evidence of intracra-
nial extension (Figure 2).  
The patient went on to have an endoscopic
assisted craniofacial resection with resection
of dural, septectomy, and bilateral medial max-
illectomies and anterior/posterior ethmoidec-
tomies. The patient was reconstructed with a
vascularized  pericranial  flap.  At  the  time  of
surgery all gross tumor was removed with mar-
gins assessed by intraoperative frozen section
assessment. The frontal lobe of brain demon-
strated no evidence of viable tumor present,
allowing for a more conservative resection in
this region. Final histopathological results of
the specimen showed the tumor to be 1.2¥0.6
cm  in  diameter  with  margins  were  free  of
tumor. Postoperatively, the patient healed well
without evidence cerebrospinal leak and con-
current adjuvant chemoradiation was initiat-
ed. The patient received 54 Gy of radiation to
the tumor bed in 27 fractions. The patient was
to receive 2 cycles of cisplatin and etoposide
protocol  concurrent  with  radiation  therapy
however because of symptoms of nausea and
extreme fatigue associated with treatment, the
second cycle of chemotherapy was withheld.
The patient has been followed clinically and
with repeated imaging for more than 8 months
and has demonstrated no evidence of disease
local recurrence (Figure 3).
Discussion
The optimal treatment modality for olfactory
neuroblastoma  continues  to  be  debated
because of limited cohort size and treatment
inconsistencies  previously  reported  in  the
medical  literature.  Earlier  staged  lesions
(Kadish A & B) have typically been described
as being treated with a monomodality regimen
such as surgery or radiation. Radical surgical
resection  has  been  shown  to  result  in
improved  5-year  survival  rates  (76.2%  vs.
14.3%)  when  compared  to  radiation  alone
when  monomodality  therapy  is  performed.
2
Tumor grade, low versus high, has been used
to direct the indication for adjuvant therapy
after surgical resection. Radiation therapy has
been  advocated  for  low-grade  lesions  with
close margins, residual and recurrent disease
and in all patients with high-grade tumors.
5
Kadish stage C patients have typically been
advocated  to  receive  combination  therapy
Case Report
Figure 1. Magnetic resonance imaging of the head at patient presentation, before receiv-
ing the neoadjuvant chemotherapy.
Figure  2.  Magnetic  resonance  imaging  of  the  head  after  receiving  the  neoadjuvant
chemotherapy, showing considerable decrease in the size of the tumor.
Figure 3. Magnetic resonance imaging of the head after surgical resection, showing no
evidence of residual tumor.[Rare Tumors 2011; 3:e1] [page 3]
such as surgery with adjuvant radiation thera-
py. The use of combined modality treatment
with surgery, radiotherapy and chemotherapy
in various combinations has been increasingly
adopted over the last two decades.
7,14,15 The use
of neoadjuvant chemotherapy for Kadish stage
C disease has been reported in retrospective
cohort  studies.
16 Various  chemotherapeutic
combination regimens have been used involv-
ing  alkylating  agents  and  anthracylines  with
significant  toxicities.
13,16 Response  to  chemo  -
therapy  may  be  dependent  upon  the  Hyam’s
grading of the original tumor. McElroy et al.
noted that high-grade olfactory neuroblastoma
was sensitive to cisplatin-based chemotherapy.
7
Fitzek et al.examined the use of neoaduj-
vant  chemotherapy  for  olfactory  neuroblas-
toma  and  neuroendocrine  carcinoma  in  19
patients with Kadish stage B [4] and C [15]
disease.
12 In this study patients received two
cycles of cisplatin (33 mg/m
2/d) and etoposide
(100  mg/m
2/d)  and  were  re-assessed  with
repeat  imaging.  A  significant  response,  of
greater than >50% reduction in tumor dimen-
sions,  (partial  or  complete)  was  seen  in  13
patients. If less than a partial response was
noted, surgical resection prior to radiotherapy
was  recommended.  Postoperatively,  the
patients  underwent  radiation  via  high-dose
proton-photon  beam  radiotherapy  to  69.2
cobalt-Gray  equivalents.  Alternatively,  if  the
patient experienced a significant response to
induction chemotherapy went directly to radio-
therapy  followed  by  2  additional  cycles  of
chemotherapy.  For  persistent  disease  after
radiation in this group, salvage surgery was
offered. With a median follow up of 45 months,
15 of the 19 patients were alive and free of dis-
ease. There were 2 local recurrences and the 5-
year local control rate and overall survival were
88% and 74% respectively. Our patient’s induc-
tion treatment parallels this study’s approach,
however  the  significant  response  to  initial
chemotherapy was used to aid surgical man-
agement of what was previously unresectable
tumor.
12
Polin et al.advocate preoperative chemoradi-
ation noting that it results in a reduced tumor
burden  and  thus  increases  the  likelihood  of
complete resection and long-term disease-free
progression.
17 In the University of Virginia pro-
tocol, 34 patients with advanced disease were
initially treated with two cycles of cyclophos-
phamide (300-650 mg/m
2) and vincristine (1-2
mg),  followed  by  50  Gy  of  radiation  therapy
prior  to  definitive  surgical  resection.  Two-
thirds  of  patients  showed  a  significant
response  in  tumor  burden  with  neoadjuvant
treatment  and  these  patients  experienced  a
lower rate of disease-related mortality when
compared  to  nonresponders.
17 Disease  free
survivals of 86.5% at 5 years and 82.6% at 15
years have been reported with this protocol.
16
These survival rates are significantly higher
than those cited for surgery followed by adju-
vant  radiation  (65%  at  5  years)  cited  by
Dulguerov et al. in their meta-analysis.
6 Kim et
al. reported on their use of neodjuvant etopo-
side  (75  mg/m
2),  cisplatin  (20  mg/m
2),  and
ifosfamide (1000 mg/m
2) for olfactory neurob-
lastoma. In their study they reported objective
responses in 9 of 11 patients (2 complete, 7
partial) with the most common significant tox-
icity being grade 3/4 neutropenia (37%).
18
Conclusions
Neoadjuvant  chemotherapy  consisting  of
etoposide and cisplatin is a potentially effective
therapeutic  option  in  the  treatment  of  locally
advanced esthesioneuroblastoma prior to surgi-
cal resection.  Due to the rarity of this tumor larg-
er, multi-institutional studies will be necessary to
validate the efficacy of this treatment in compar-
ison  to  current  protocols  using  chemotherapy
exclusively in the adjuvant setting.
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